WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., PhD., President and Chief Executive Officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10th at 2:15 pm PT / 5:15 pm ET.
A live webcast of the presentation will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.
About Disc Medicine
Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
Media Contact
Peg Rusconi
Verge Scientific Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact
Christina Tartaglia
Stern Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$63.50 |
Daily Change: | -1.50 -2.31 |
Daily Volume: | 254,119 |
Market Cap: | US$1.890B |
December 09, 2024 November 12, 2024 November 08, 2024 November 05, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB